Business Context and Reporting Period
This Form 8-K filing by Enanta Pharmaceuticals, Inc. covers the event date of November 22, 2013. The report addresses a change in the company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and does not contain financial performance data.
Material Changes
On November 22, 2013, Helmut M. Schühsler submitted his resignation as a director of Enanta Pharmaceuticals, Inc., effective immediately. Dr. Schühsler also served on the Compensation Committee and the Nominating and Corporate Governance Committee. The company stated that the resignation was not the result of any disagreement with Enanta regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the director departure.
Investor Verification Checklist
- Verify the effective date of Dr. Schühsler's resignation (November 22, 2013).
- Confirm the committees from which Dr. Schühsler stepped down (Compensation and Nominating/Corporate Governance).
- Check for any subsequent filings regarding the appointment of a replacement director.
- Review the company's most recent 10-Q or 10-K for financial metrics, as this 8-K does not include them.